Bridge to Life Expands Impact in Organ Preservation Technology

Bridge to Life Enhances Organ Preservation Capabilities

Bridge to Life Ltd., a recognized leader in organ preservation solutions and perfusion technology, has taken a significant step forward by acquiring the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A. This strategic acquisition not only strengthens the company's commitment to advancing transplant medicine but also solidifies its enterprise value in the healthcare market.

Milestone in Transplant Technology

The acquisition of the VitaSmart™ system represents a game-changing milestone for Bridge to Life's efforts in organ preservation. The system has successfully facilitated over 5,000 liver perfusions globally, utilizing Hypothermic Oxygenated Perfusion (HOPE) techniques, thus showcasing its effectiveness in preserving organ viability. This remarkable achievement highlights the technology's potential to transform organ transplant practices.

Bridge to Life CEO's Vision

Don Webber, CEO and President of Bridge to Life Ltd, expressed excitement over the acquisition, emphasizing the technology's user-friendly design and minimal monitoring requirements. "The VitaSmart™ system has empowered clinicians to implement HOPE protocols with remarkable efficiency," he stated. By leveraging this technology, Bridge to Life aims to enhance transplant outcomes and ultimately save more lives.

Focus on FDA Submission

As part of their commitment to advancing medical technology, Bridge to Life is in the final stages of preparing its FDA submission for the VitaSmart™ system. The company targets the first quarter of 2025 for this submission. Webber noted, "The results from our pivotal U.S. study are promising, showing statistical superiority in early allograft dysfunction and reduced hospital stays post-transplant. This acquisition positions us to better serve U.S. transplant centers and organ procurement organizations, ensuring patients have access to this transformative technology."

Commitment to Global Health

This acquisition aligns seamlessly with Bridge to Life’s mission to improve transplantation outcomes. The ability to provide innovative solutions for organ preservation is essential, especially for patients in need. Administration of the VitaSmart™ technology positions Bridge to Life as a forerunner in the field, meeting the growing global demand for effective organ preservation methods.

About Medica S.p.A.

Medica S.p.A., based in the biomedical district of Mirandola, Italy, is a premier biomedical and MedTech group known for its dedication to developing high-tech products for blood and water purification. The company has established a strong international presence and is committed to innovation in healthcare technology.

About Bridge to Life Ltd

Established as a market leader, Bridge to Life Ltd specializes in organ preservation solutions. The company offers a range of high-quality products, including the Belzer UW® and EasiSlush®, alongside the VitaSmart™ Machine Perfusion System. Their dedication to quality, innovation, and accessibility helps them serve leading Transplant Centers and Organ Procurement Offices worldwide.

Frequently Asked Questions

What technology did Bridge to Life acquire?

Bridge to Life acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.

What is the significance of the VitaSmart™ system?

The VitaSmart™ system has successfully conducted over 5,000 liver perfusions and demonstrates effectiveness in organ preservation, revolutionizing transplant practices.

When does Bridge to Life plan to submit to the FDA?

Bridge to Life is finalizing its FDA submission for the VitaSmart™ system, targeting the first quarter of 2025.

What are the expected outcomes from the U.S. study?

The U.S. study has shown promising results, including reduced early allograft dysfunction rates and shorter hospital stays for transplant recipients.

How does this acquisition align with Bridge to Life's mission?

This acquisition enhances their commitment to improving transplantation outcomes and expanding access to innovative organ preservation technologies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.